File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: ARX-associated infantile epileptic-dyskinetic encephalopathy with responsiveness to valproate for controlling seizures and reduced activity of muscle mitochondrial complex IV

TitleARX-associated infantile epileptic-dyskinetic encephalopathy with responsiveness to valproate for controlling seizures and reduced activity of muscle mitochondrial complex IV
Authors
KeywordsARX
Aristaless-related homeobox
Infantile epileptic-dyskinetic encephalopathy
Mitochondrial dysfunction
Pyridoxal phosphate
Issue Date2019
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/braindev
Citation
Brain & Development, 2019, v. 41 n. 10, p. 883-887 How to Cite?
AbstractBackground: ARX genetic defect is associated with a spectrum of neurodevelopmental disorders that exhibit a high degree of phenotypic heterogeneity. Methods: We studied a family with a 13-year old Chinese boy and his two elder brothers presented with infantile epileptic-dyskinetic encephalopathy and clarified the unknown genetic etiology of the youngest brother by whole exome sequencing. Results: The youngest brother of this family presented with developmental regression, dystonia, epilepsy, microcephaly, visual impairment and oromotor dysfunction. Hyperlactataemia, raised alanine and muscle complex IV deficiency indicated that he had mitochondrial dysfunction. Likely pathogenic hemizygous missense ARX variants (c.989G>A; p.Arg330His) located in conserved nuclear localization sequence was identified. The variant was carried by his asymptomatic mother and not found in his asymptomatic third elder brother. The intractable seizures showed complete but transient responsiveness to pyridoxal phosphate and finally controlled by valproate treatment. Conclusion: This is the first case of ARX-associated encephalopathy showing mitochondrial dysfunction and transient responsiveness to pyridoxal phosphate treatment.
Persistent Identifierhttp://hdl.handle.net/10722/272703
ISSN
2023 Impact Factor: 1.4
2023 SCImago Journal Rankings: 0.498
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKwong, AKY-
dc.contributor.authorChu, VLY-
dc.contributor.authorRODENBURG, RJT-
dc.contributor.authorSMEITINK, J-
dc.contributor.authorFung, CW-
dc.date.accessioned2019-08-06T09:14:57Z-
dc.date.available2019-08-06T09:14:57Z-
dc.date.issued2019-
dc.identifier.citationBrain & Development, 2019, v. 41 n. 10, p. 883-887-
dc.identifier.issn0387-7604-
dc.identifier.urihttp://hdl.handle.net/10722/272703-
dc.description.abstractBackground: ARX genetic defect is associated with a spectrum of neurodevelopmental disorders that exhibit a high degree of phenotypic heterogeneity. Methods: We studied a family with a 13-year old Chinese boy and his two elder brothers presented with infantile epileptic-dyskinetic encephalopathy and clarified the unknown genetic etiology of the youngest brother by whole exome sequencing. Results: The youngest brother of this family presented with developmental regression, dystonia, epilepsy, microcephaly, visual impairment and oromotor dysfunction. Hyperlactataemia, raised alanine and muscle complex IV deficiency indicated that he had mitochondrial dysfunction. Likely pathogenic hemizygous missense ARX variants (c.989G>A; p.Arg330His) located in conserved nuclear localization sequence was identified. The variant was carried by his asymptomatic mother and not found in his asymptomatic third elder brother. The intractable seizures showed complete but transient responsiveness to pyridoxal phosphate and finally controlled by valproate treatment. Conclusion: This is the first case of ARX-associated encephalopathy showing mitochondrial dysfunction and transient responsiveness to pyridoxal phosphate treatment.-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/braindev-
dc.relation.ispartofBrain & Development-
dc.subjectARX-
dc.subjectAristaless-related homeobox-
dc.subjectInfantile epileptic-dyskinetic encephalopathy-
dc.subjectMitochondrial dysfunction-
dc.subjectPyridoxal phosphate-
dc.titleARX-associated infantile epileptic-dyskinetic encephalopathy with responsiveness to valproate for controlling seizures and reduced activity of muscle mitochondrial complex IV-
dc.typeArticle-
dc.identifier.emailKwong, AKY: kkyanna@hku.hk-
dc.identifier.emailChu, VLY: vchu@hkucc.hku.hk-
dc.identifier.emailFung, CW: fcw1209m@hku.hk-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.braindev.2019.07.003-
dc.identifier.pmid31324350-
dc.identifier.scopuseid_2-s2.0-85068873126-
dc.identifier.hkuros300758-
dc.identifier.hkuros320450-
dc.identifier.volume41-
dc.identifier.issue10-
dc.identifier.spage883-
dc.identifier.epage887-
dc.identifier.isiWOS:000500652800008-
dc.publisher.placeNetherlands-
dc.identifier.issnl0387-7604-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats